ID   iPS-DF19-9-7T
AC   CVCL_K055
SY   iPS DF19-9-7T; iPS DF19-9-7T-PCBC; DF19-9-7T; DF-19-9-7T; iPS DF 19.7; DF19.7; WAi001-B; PCBC02hsi2011100701; SC11-016
DR   EFO; EFO_0007095
DR   BioSamples; SAMEA6260528
DR   ENCODE; ENCBS858DVB
DR   hPSCreg; WAi001-B
DR   ISCR; 2125
DR   SKIP; SKIP005451
DR   WiCell; ips-df19-9-7t
DR   WiCell; ips-df19-9-7t-pcbc
DR   Wikidata; Q54898099
RX   PubMed=19325077;
RX   PubMed=21296996;
RX   PubMed=21983960;
RX   PubMed=26670276;
RX   PubMed=27293150;
CC   Part of: NHBLI Progenitor Cell Biology Consortium (PCBC) collection.
CC   From: University of Wisconsin; Madison; USA.
CC   Omics: Deep phosphoproteome analysis.
CC   Omics: Deep proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Derived from site: In situ; Foreskin, skin; UBERON=UBERON_0001471.
CC   Cell type: Fibroblast of foreskin; CL=CL_1001608.
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_4T92 ! iPS-DF19-9
SX   Male
AG   <1M
CA   Induced pluripotent stem cell
DT   Created: 11-02-13; Last updated: 29-06-23; Version: 22
//
RX   PubMed=19325077; DOI=10.1126/science.1172482;
RA   Yu J.-Y., Hu K.-J., Smuga-Otto K., Tian S.-L., Stewart R.,
RA   Slukvin I.I., Thomson J.A.;
RT   "Human induced pluripotent stem cells free of vector and transgene
RT   sequences.";
RL   Science 324:797-801(2009).
//
RX   PubMed=21296996; DOI=10.1182/blood-2010-07-298331;
RA   Hu K.-J., Yu J.-Y., Suknuntha K., Tian S.-L., Montgomery K., Choi K.-D.,
RA   Stewart R., Thomson J.A., Slukvin I.I.;
RT   "Efficient generation of transgene-free induced pluripotent stem cells
RT   from normal and neoplastic bone marrow and cord blood mononuclear
RT   cells.";
RL   Blood 117:E109-E119(2011).
//
RX   PubMed=21983960; DOI=10.1038/nmeth.1699;
RA   Phanstiel D.H., Brumbaugh J., Wenger C.D., Tian S.-L., Probasco M.D.,
RA   Bailey D.J., Swaney D.L., Tervo M.A., Bolin J.M., Ruotti V.,
RA   Stewart R., Thomson J.A., Coon J.J.;
RT   "Proteomic and phosphoproteomic comparison of human ES and iPS
RT   cells.";
RL   Nat. Methods 8:821-827(2011).
//
RX   PubMed=26670276; DOI=10.1038/mtna.2015.42;
RA   Kang H., Minder P., Park M.A., Mesquitta W.-T., Torbett B.E.,
RA   Slukvin I.I.;
RT   "CCR5 disruption in induced pluripotent stem cells using CRISPR/Cas9
RT   provides selective resistance of immune cells to CCR5-tropic HIV-1
RT   virus.";
RL   Mol. Ther. Nucleic Acids 4:e268.1-e268.10(2015).
//
RX   PubMed=27293150; DOI=10.1016/j.stemcr.2016.05.006;
RA   Salomonis N., Dexheimer P.J., Omberg L., Schroll R., Bush S., Huo J.,
RA   Schriml L.M., Sui S.H., Keddache M., Mayhew C.N., Shanmukhappa S.K.,
RA   Wells J.M., Daily K., Hubler S., Wang Y.-L., Zambidis E.T., Margolin A.A.,
RA   Hide W.A., Hatzopoulos A.K., Malik P., Cancelas J.A., Aronow B.J.,
RA   Lutzko C.;
RT   "Integrated genomic analysis of diverse induced pluripotent stem cells
RT   from the Progenitor Cell Biology Consortium.";
RL   Stem Cell Reports 7:110-125(2016).
//